Uveal melanoma is the most common intraocular malignancy and arises from melanocytes in the choroid, ciliary body, or iris. The current eye-sparing treatment options include surgical treatment, plaque brachytherapy, proton beam radiotherapy, stereotactic photon radiotherapy, or photodynamic therapy. However, the efficacy of these methods is still unsatisfactory. This article reviews several possible new treatment options and their potential advantages in treating localized uveal melanoma. These methods may be based on the physical destruction of the cancerous cells by applying ultrasounds. Two examples of such an approach are High-Intensity Focused Ultrasound (HIFU)—a promising technology of thermal destruction of solid tumors located deep under the skin and sonodynamic therapy (SDT) that induces reactive oxygen species. Another approach may be based on improving the penetration of anti-cancer agents into UM cells. The most promising technologies from this group are based on enhancing drug delivery by applying electric current. One such approach is called transcorneal iontophoresis and has already been shown to increase the local concentration of several different therapeutics. Another technique, electrically enhanced chemotherapy, may promote drug delivery from the intercellular space to cells. Finally, new advanced nanoparticles are developed to combine diagnostic imaging and therapy (i.e., theranostics). However, development. these methods More are mostly advanced at an and early targeted stage of preclinical development. studies More and advanced clinical trials and targeted would be preclinical needed to studies introduce and some clinical of trials these would techniques be needed to routine to introduce clinical practice. some of these techniques to routine clinical practice.
New perspectives for eye-sparing treatment strategies in primary uveal melanoma / Bilmin, K.; Synoradzki, K. J.; Czarnecka, A. M.; Spalek, M. J.; Kujawska, T.; Solnik, M.; Merks, P.; Toro, M. D.; Rejdak, R.; Fiedorowicz, M.. - In: CANCERS. - ISSN 2072-6694. - 14:1(2022), p. 134. [10.3390/cancers14010134]
New perspectives for eye-sparing treatment strategies in primary uveal melanoma
Toro M. D.;
2022
Abstract
Uveal melanoma is the most common intraocular malignancy and arises from melanocytes in the choroid, ciliary body, or iris. The current eye-sparing treatment options include surgical treatment, plaque brachytherapy, proton beam radiotherapy, stereotactic photon radiotherapy, or photodynamic therapy. However, the efficacy of these methods is still unsatisfactory. This article reviews several possible new treatment options and their potential advantages in treating localized uveal melanoma. These methods may be based on the physical destruction of the cancerous cells by applying ultrasounds. Two examples of such an approach are High-Intensity Focused Ultrasound (HIFU)—a promising technology of thermal destruction of solid tumors located deep under the skin and sonodynamic therapy (SDT) that induces reactive oxygen species. Another approach may be based on improving the penetration of anti-cancer agents into UM cells. The most promising technologies from this group are based on enhancing drug delivery by applying electric current. One such approach is called transcorneal iontophoresis and has already been shown to increase the local concentration of several different therapeutics. Another technique, electrically enhanced chemotherapy, may promote drug delivery from the intercellular space to cells. Finally, new advanced nanoparticles are developed to combine diagnostic imaging and therapy (i.e., theranostics). However, development. these methods More are mostly advanced at an and early targeted stage of preclinical development. studies More and advanced clinical trials and targeted would be preclinical needed to studies introduce and some clinical of trials these would techniques be needed to routine to introduce clinical practice. some of these techniques to routine clinical practice.File | Dimensione | Formato | |
---|---|---|---|
cancers-14-00134 (1).pdf
accesso aperto
Tipologia:
Versione Editoriale (PDF)
Licenza:
Dominio pubblico
Dimensione
1.76 MB
Formato
Adobe PDF
|
1.76 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.